1. Home
  2. GDL vs ICCC Comparison

GDL vs ICCC Comparison

Compare GDL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GDL Fund The of Beneficial Interest

GDL

GDL Fund The of Beneficial Interest

SELL

Current Price

$8.49

Market Cap

90.7M

Sector

Finance

ML Signal

SELL

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$10.21

Market Cap

75.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDL
ICCC
Founded
2006
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.7M
75.8M
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
GDL
ICCC
Price
$8.49
$10.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.6K
25.8K
Earning Date
01-01-0001
05-15-2026
Dividend Yield
6.02%
N/A
EPS Growth
N/A
53.85
EPS
N/A
N/A
Revenue
N/A
$26,493,169.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
51.64
52 Week Low
$8.19
$4.52
52 Week High
$8.67
$10.25

Technical Indicators

Market Signals
Indicator
GDL
ICCC
Relative Strength Index (RSI) 54.91 78.28
Support Level $8.39 $5.85
Resistance Level $8.53 N/A
Average True Range (ATR) 0.05 0.45
MACD -0.00 0.10
Stochastic Oscillator 58.88 99.56

Price Performance

Historical Comparison
GDL
ICCC

About GDL GDL Fund The of Beneficial Interest

GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: